Search results
Results from the WOW.Com Content Network
The analyst anticipates that Pfizer’s management will guide to EPS in the mid-to-high $2 range with core business growth offset by the $0.30 in favorable but non-recurring items during 2024 ...
Pfizer (NYSE: PFE) stock investors are curious about the valuation and prospects for the healthcare company. Stock prices used were the afternoon prices of Jan. 1, 2025. The video was published on ...
It now expects earnings per share between $2.15 and $2.35. That's up from previous guidance of between $2.05 and $2.25. That's up from previous guidance of between $2.05 and $2.25.
Pfizer (PFE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
The vaccination wave peaked earlier this year, and revenue/earnings are expected to drop in 2023.InvestorPlace - Stock Mark 3 Reasons Why It’s a Good Time to Buy PFE Stock Skip to main content
For premium support please call: 800-290-4726 more ways to reach us
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Pfizer (PFE) delivered earnings and revenue surprises of 21.09% and 7.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?